BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 30054143)

  • 1. Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease.
    Núñez-Gómez L; Mesonero-Gismero F; Albillos-Martínez A; López-Sanromán A
    Gastroenterol Hepatol; 2018 Nov; 41(9):576-582. PubMed ID: 30054143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications and surgery in the inflammatory bowel diseases biological era.
    Sokol H; Seksik P; Cosnes J
    Curr Opin Gastroenterol; 2014 Jul; 30(4):378-84. PubMed ID: 24840000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of tumor necrosis factor-alpha inhibitors in fistulising perianal Crohn's disease].
    Bor R; Farkas K; Bálint A; Szűcs M; Abrahám S; Baradnay G; Wittmann T; Szepes Z; Nagy F; Molnár T
    Orv Hetil; 2013 Dec; 154(49):1943-8. PubMed ID: 24292112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
    Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
    Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New advances in the treatment of inflammatory bowel disease].
    Chaparro M
    Gastroenterol Hepatol; 2013 Oct; 36 Suppl 2():21-9. PubMed ID: 24160949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
    Papamichael K; Cheifetz AS
    World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.
    Barnes EL; Goldin A; Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
    Dig Dis Sci; 2016 Nov; 61(11):3261-3269. PubMed ID: 27639871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
    Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
    J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
    Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
    Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of inflammatory bowel disease in an Israeli Arab population.
    Zvidi I; Fraser GM; Niv Y; Birkenfeld S
    J Crohns Colitis; 2013 Jun; 7(5):e159-63. PubMed ID: 22921466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly.
    Sturm A; Maaser C; Mendall M; Karagiannis D; Karatzas P; Ipenburg N; Sebastian S; Rizzello F; Limdi J; Katsanos K; Schmidt C; Jeuring S; Colombo F; Gionchetti P
    J Crohns Colitis; 2017 Mar; 11(3):263-273. PubMed ID: 27797918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on idiopathic colitides.
    Strobel S; Abreu MT
    Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review.
    Martín-García P; Alonso-Arroyo A; Catalá-López F
    Med Clin (Barc); 2023 Jun; 160(11):501-516. PubMed ID: 36967304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.